Local ablative treatments, and in particular radiotherapy, may also play a role in the first-line treatment of patients with EGFR-mutated NSCLC, both to treat any residual disease after a good partial response to TKIs, and to be used upfront together with TKIs, in case of oligometastatic disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.